JP2020530282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530282A5 JP2020530282A5 JP2020500057A JP2020500057A JP2020530282A5 JP 2020530282 A5 JP2020530282 A5 JP 2020530282A5 JP 2020500057 A JP2020500057 A JP 2020500057A JP 2020500057 A JP2020500057 A JP 2020500057A JP 2020530282 A5 JP2020530282 A5 JP 2020530282A5
- Authority
- JP
- Japan
- Prior art keywords
- uricase
- replaced
- utilis
- recombinant
- recombinant variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010092464 Urate Oxidase Proteins 0.000 claims description 79
- 241000735249 Madhuca utilis Species 0.000 claims description 24
- 241000235646 Cyberlindnera jadinii Species 0.000 claims description 21
- 235000004279 alanine Nutrition 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 13
- 102220357239 c.151G>A Human genes 0.000 claims description 13
- 235000013922 glutamic acid Nutrition 0.000 claims description 13
- 239000004220 glutamic acid Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- 235000003704 aspartic acid Nutrition 0.000 claims description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 8
- 229960000310 isoleucine Drugs 0.000 claims description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- 201000005569 Gout Diseases 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- 108010019160 Pancreatin Proteins 0.000 claims description 5
- 229940116731 Uricosuric agent Drugs 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 229940055695 pancreatin Drugs 0.000 claims description 5
- 239000003383 uricosuric agent Substances 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 239000006201 parenteral dosage form Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229940116269 uric acid Drugs 0.000 claims description 4
- 102220518628 Baculoviral IAP repeat-containing protein 6_T47E_mutation Human genes 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006207 intravenous dosage form Substances 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 102200038952 rs3762568 Human genes 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 201000001431 Hyperuricemia Diseases 0.000 description 8
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- -1 (d) at position 51 Chemical compound 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical group OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical group CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023109386A JP2023126877A (ja) | 2017-07-07 | 2023-07-03 | 組換えウリカーゼ酵素 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529726P | 2017-07-07 | 2017-07-07 | |
| US62/529,726 | 2017-07-07 | ||
| US201862678511P | 2018-05-31 | 2018-05-31 | |
| US62/678,511 | 2018-05-31 | ||
| PCT/US2018/041015 WO2019010369A1 (en) | 2017-07-07 | 2018-07-06 | RECOMBINANT ENZYME URICASE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023109386A Division JP2023126877A (ja) | 2017-07-07 | 2023-07-03 | 組換えウリカーゼ酵素 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530282A JP2020530282A (ja) | 2020-10-22 |
| JP2020530282A5 true JP2020530282A5 (enExample) | 2021-08-12 |
Family
ID=64951239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500057A Pending JP2020530282A (ja) | 2017-07-07 | 2018-07-06 | 組換えウリカーゼ酵素 |
| JP2023109386A Pending JP2023126877A (ja) | 2017-07-07 | 2023-07-03 | 組換えウリカーゼ酵素 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023109386A Pending JP2023126877A (ja) | 2017-07-07 | 2023-07-03 | 組換えウリカーゼ酵素 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200308534A1 (enExample) |
| EP (1) | EP3655527A4 (enExample) |
| JP (2) | JP2020530282A (enExample) |
| CN (1) | CN111373034A (enExample) |
| AU (1) | AU2018297309A1 (enExample) |
| CA (1) | CA3069197A1 (enExample) |
| IL (1) | IL271813A (enExample) |
| WO (1) | WO2019010369A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112646790A (zh) * | 2019-10-11 | 2021-04-13 | 上海君实生物医药科技股份有限公司 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
| US20230105474A1 (en) * | 2020-02-25 | 2023-04-06 | Synlogic Operating Company, Inc. | Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof |
| KR20230110281A (ko) | 2020-11-03 | 2023-07-21 | 프로탈릭스 리미티드 | 변형된 유리카제(uricase) 및 이의 용도 |
| CN114480320B (zh) * | 2022-02-28 | 2024-01-16 | 复旦大学 | 重组夜猴尿酸酶及其应用 |
| CN118497162B (zh) * | 2024-05-24 | 2025-05-16 | 广东少和生物科技有限公司 | 黑酵母菌尿酸氧化酶及其突变体和应用 |
| CN119876069B (zh) * | 2025-03-12 | 2025-10-21 | 开平牵牛生化制药有限公司 | 具有高活性且免疫原性弱化的人源尿酸氧化酶突变体 |
| CN119876071B (zh) * | 2025-03-12 | 2025-10-21 | 开平牵牛生化制药有限公司 | 低免疫原性的高活性人源尿酸氧化酶突变体 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3462313B2 (ja) * | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法 |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| CA2338665C (en) | 1998-08-06 | 2011-01-18 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| US20050049166A1 (en) * | 2003-08-29 | 2005-03-03 | Huang Tsao-Chin Clare | Enzyme-based cleaning composition and method of use |
| GB0326676D0 (en) * | 2003-11-15 | 2003-12-17 | Astrazeneca Ab | Protein |
| CN1980687B (zh) * | 2004-02-09 | 2015-05-13 | 人类基因科学公司 | 清蛋白融合蛋白 |
| WO2006012438A2 (en) | 2004-07-21 | 2006-02-02 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of insulin resistance |
| WO2008051178A2 (en) | 2006-04-12 | 2008-05-02 | Savient Pharmaceuticals, Inc. | Purification of proteins with cationic surfactant |
| US20110171268A1 (en) * | 2008-03-24 | 2011-07-14 | Althea Technologies, Inc. | Uricase compositions and methods of use |
| CN101390969A (zh) * | 2008-11-03 | 2009-03-25 | 中国人民解放军军事医学科学院生物工程研究所 | 降低血液中尿酸浓度的药物 |
| CN101875922B (zh) * | 2009-04-30 | 2012-02-22 | 重庆医科大学 | 一种重组苛求芽孢杆菌胞内尿酸酶及其聚乙二醇修饰与应用 |
| EP4635567A3 (en) | 2009-06-25 | 2025-12-03 | Horizon Therapeutics USA, Inc. | Methods and kits for preventing infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| CN109706217B (zh) * | 2010-02-05 | 2022-12-09 | 新英格兰生物实验室公司 | 高保真性限制性内切核酸酶 |
| CN102586315A (zh) * | 2012-02-21 | 2012-07-18 | 章泽人 | 一种低尿酸分泌量益生菌及其制备方法 |
| EP2986720B1 (en) * | 2013-04-17 | 2017-09-06 | Council of Scientific & Industrial Research | Uricase mutants |
| CN104342415A (zh) * | 2014-07-08 | 2015-02-11 | 吉林省金梓源生物科技有限公司 | 一种重组尿酸酶的制备方法 |
| AR101504A1 (es) * | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
| CN106554948B (zh) | 2015-09-29 | 2019-06-25 | 上海生物制品研究所有限责任公司 | 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用 |
| IL318183A (en) | 2016-03-11 | 2025-03-01 | Selecta Biosciences Inc | Formulations and doses of pegylated uricase |
| CN110234340A (zh) | 2016-11-11 | 2019-09-13 | 好利恩风湿病制药有限责任公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| CN107308452A (zh) * | 2017-05-29 | 2017-11-03 | 钟术光 | 一种稳定生物活性材料的组合物的制备方法 |
| GB201713732D0 (en) * | 2017-08-25 | 2017-10-11 | Alta Innovations Ltd | Tat expression system |
| CN109223707B (zh) | 2018-09-13 | 2020-12-08 | 中国药科大学 | 一种尿酸酶外用凝胶制剂、其制备方法及用途 |
| CN109846909B (zh) * | 2019-01-31 | 2022-03-22 | 武汉康复得生物科技股份有限公司 | 可在肠道中催化尿酸降解的组合物及其制备方法和应用 |
| KR20250041198A (ko) * | 2019-05-10 | 2025-03-25 | 피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭) | 폴리에틸렌 글리콜로 변형된 요산 산화효소 |
-
2018
- 2018-07-06 WO PCT/US2018/041015 patent/WO2019010369A1/en not_active Ceased
- 2018-07-06 AU AU2018297309A patent/AU2018297309A1/en not_active Abandoned
- 2018-07-06 JP JP2020500057A patent/JP2020530282A/ja active Pending
- 2018-07-06 EP EP18827590.3A patent/EP3655527A4/en not_active Withdrawn
- 2018-07-06 CA CA3069197A patent/CA3069197A1/en active Pending
- 2018-07-06 CN CN201880054605.5A patent/CN111373034A/zh active Pending
- 2018-07-06 US US16/628,743 patent/US20200308534A1/en not_active Abandoned
-
2019
- 2019-11-05 US US16/674,325 patent/US10815461B2/en active Active
-
2020
- 2020-01-02 IL IL271813A patent/IL271813A/en unknown
-
2023
- 2023-07-03 JP JP2023109386A patent/JP2023126877A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530282A5 (enExample) | ||
| JP2020203926A5 (enExample) | ||
| Verhelst et al. | Mx proteins: antiviral gatekeepers that restrain the uninvited | |
| Lee et al. | Polymer structure and conformation alter the antigenicity of virus-like particle–polymer conjugates | |
| US20210299211A1 (en) | Peptidomimetic macrocycles and formulations thereof | |
| CN104507489B (zh) | 用于预防和治疗类风湿性关节炎的组合物 | |
| ES2602618T3 (es) | Composiciones de fenilalanina amoníaco-liasa procariótica y métodos de tratamiento del cáncer que usan composiciones de la misma | |
| JP2016538885A5 (enExample) | ||
| JP2018515101A5 (enExample) | ||
| JP2015513897A5 (enExample) | ||
| JP2019194251A5 (enExample) | ||
| JP2020023567A5 (enExample) | ||
| FI3642340T3 (fi) | Muunneltu l-asparaginaasi | |
| JP2018522563A5 (enExample) | ||
| JP2017221201A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| JP2018506286A5 (enExample) | ||
| JP2004534503A5 (enExample) | ||
| JP2014529399A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| KR101746160B1 (ko) | 결핵균 독소-항독소 체계를 표적으로 하는 항생 펩타이드 및 이의 용도 | |
| JP2017500885A5 (enExample) | ||
| JP2020518249A5 (enExample) | ||
| JP2017503505A5 (enExample) | ||
| ES2742179T3 (es) | Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino |